1.Treatment for underlying diseases: weight loss (weight control/waist circumference reduction); improve IR, lower blood sugar; adjust blood lipids; lower blood pressure (cloxacin); lower blood viscosity, lower uric acid, as well as anti-inflammatory (hormone cocaine), anti-platelet (aspirin), of which waist circumference reduction is the most important. 2.Avoid aggravating liver damage: reduce alcohol consumption; pay attention to waist circumference; use drugs carefully; maintain intestinal microecological balance; ensure liver blood supply, oxygen supply and energy supply; prevent viral hepatitis. 3, drug treatment for liver disease: aim to improve the ability of SFL to prevent “second strike”, reduce the degree of hepatocyte damage and inflammatory necrosis in NASH, the mechanism involves repairing biofilm, antagonizing oxygen stress/lipid peroxidation, anti-inflammatory, anti-apoptotic, anti-fibrosis and so on. However, it is difficult for existing drugs to effectively reduce hepatic lipid content and to provide hepatoprotective, anti-inflammatory, and anti-fibrotic effects alone. Indications for hepatoprotective drugs in NAFLD: (1) abnormal liver function; (2) combined metabolic syndrome; (3) NASH rather than SFL confirmed by liver biopsy; (4) ineffective basic therapy for six months or the treatment used may induce and lead to worsening of liver disease; (5) presence of symptoms associated with chronic liver disease. The use of polyenophosphatidylcholine (ezanadine), ursodeoxycholic acid (Eusebio), silymarin, and vitamin E is recommended; the use of pentamidine class enzyme-lowering drugs alone is not recommended. Generally, one or two liver-protective drugs are used for more than six months, or until liver enzymes are normalized or inflammation and fibrosis in the liver subsides on liver biopsy.